Thomas Jefferson University

Nova Southeastern University

Anastasios Lymperopoulos

Walter J Koch

The invention concerns the contribution of elevated levels of circulating alsosterone to heart disease and other hyperaldosteronic conditions. Since activation of &#x3b2;-arrestin 1(&#x3b2;arr1) by the Angiotensin II (AngII) type 1 receptor (ATR) mediates AngII-induced aldosterone production, &#x3b2;-arrestin 1(&#x3b2;arr1) is a therapeutic target for heart disease. The invention provides a &#x3b2;arr1 protein fragment comprising the C-terminus of &#x3b2;arr1 (&#x3b2;arr1ct; SEQ ID NO:3), compositions containing this protein fragment, and methods of using this protein fragment to reduce elevated levels of aldosterone in heart disease and other hyperaldosteronic conditions by inhibition of &#x3b2;-arrestin 1(&#x3b2;arr1). These compositions and methods are of therapeutic benefit in chronic heart failure and progression to heart failure after myocardial infarction (MI). Additionally, the invention provides an AngII peptide analog (SEQ ID NO:4), compositions containing this analog, and methods of using this analog for stimulation of &#x3b2;arr1 activity and aldosterone production.

Growing community of inventors

Fort Lauderdale, FL, United States of America

Anastasios Lymperopoulos